Appropriateness of gastroscopy: Dyspepsia

Endoscopy

Volumn 31, Issue 8, 1999, Pages 579-595

  Froehlich, Florian ^a   Bochud, M ^b   Gonvers, J J ^a   Dubois, R W ^c   Vader, J P ^b   Wietlisbach, V ^c   Burnand, B ^b  

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Protocare Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

DYSPEPSIA; ERADICATION THERAPY; GASTRODUODENAL ULCER; GASTROINTESTINAL INFECTION; GASTROSCOPY; HELICOBACTER PYLORI; PRIORITY JOURNAL; REVIEW; CLINICAL PRACTICE; HELICOBACTER INFECTION; HUMAN; ISOLATION AND PURIFICATION; PEPTIC ULCER; PREDICTION AND FORECASTING; STOMACH TUMOR; UTILIZATION REVIEW;

DYSPEPSIA; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PREDICTIVE VALUE OF TESTS; STOMACH NEOPLASMS;

EID: 0032589929     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-1999-62     Document Type: Review

References (167)

1. Vader JP, Burnand B, Froehlich F, et al. The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): Project and Methods. Endoscopy 1999; 31: 572-578
2. Vader JP, Froehlich F, Dubois RW, et al. The European Panel on Appropriateness of Gastrointestinal Ensocopy (EPAGE): Conclusions and WWW site. Endoscopy 1999; 31: 687-694
3. Morrissey JF, Reichelderfer M. Gastrointestinal endoscopy (2). N Engl J Med 1991; 325: 1214-1222
4. Colin-Jones DG. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576-579
5. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988; 108: 865-879
6. Barbara L, Camilleri M, Corinaldesi R, et al. Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci 1989; 34: 1272-1276
7. Malfertheiner P, McColl K, Baldi F, et al. Update on Helicobacter pylori research. Dyspepsia. Eur J Gastroenterol Hepatol 1997; 9: 624-625
8. Agreus L, Engstrand L, Svardsudd K, et al. Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms. A population-based epidemiologic study. Scan J Gastroenterol 1995; 30: 752-757
9. Veldhuyzen van Zanten SJ, Tytgat KM, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993; 46: 273-279
10. Bochud M, Gonvers JJ, Vader JP, et al. Appropriateness of gastroscopy: Gastroesophageal reflux disease. Endoscopy 1999; 31: 596-603
11. Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992; 136: 165-177
12. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-1268
13. Jones RH, Lydeard SE, Hobbs FD, et al. Dyspepsia in England and Scotland. Gut 1990; 3: 401-405
14. Knill-Jones RP. Geographical differences in the prevalence of dyspepsia. Scan J Gastroenterol 1991; 26: 17-24
15. Jones R. Dyspeptic symptoms in the community. Gut 1989; 30: 893-898
16. Johnsen R, Bernersen B, Straume B, et al. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ 1991; 302: 749-752
17. Vaira D, Stanghellini V, Menegatti M, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology: a safe policy? The Italian Helicobacter pylori Study Group. Endoscopy 1997; 29: 595-601
18. Patel P, Mendall MA, Khulusi S, et al. Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. Lancet 1994; 344: 511-512
19. Sobala GM, Crabtree JE, Pentith JA, et al. Screening dyspepsia by serology to Helicobacter pylori. Lancet 1991; 338: 94-96
20. Heikkinen M, Pikkarainen P, Takala J, et al. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scan J Gastroenterol 1995; 30: 519-523
21. Mansi C, Mela GS, Savarino V, et al. Open access endoscopy: a large-scale analysis of its use in dyspeptic patients. J Clin Gastroenterol 1993; 16: 149-153
22. Bernersen B, Johnsen R, Bostad L, et al. Is Helicobacter pylori the cause of dyspepsia? BMJ 1992; 304: 1276-1279
23. Talley NJ, Weaver AL, Tesmer DL, et al. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378-1386
24. Hansen JM, Bytzer P, Bondesen S, et al. Efficacy and outcome of an open access endoscopy service. Dan Med Bull 1991; 38: 288-290
25. Fraser AG, Ali MR, McCullough S, et al. Diagnostic tests for Helicobacter pylori - can they help select patients for endoscopy? New Zealand Medical Journal 1996; 109: 95-98
26. Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108: 917-924
27. Richter JE. Dyspepsia: organic causes and differential characteristics from functional dyspepsia. (Review) Scand J Gastroenterol Suppl 1991; 182: 11-16
28. Williams B, Luckas M, Ellingham JH, et al. Do young patients with dyspepsia need investigation? Lancet 1988; 2: 1349-1351
29. Bytzer P, Schaffalitzky de Muckadell OB. Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring system. Scan J Gastroenterol 1992; 27: 987-992
30. Kalra L, Price WR, Jones BJ, Hamlyn AN. Open access fibresigmoidoscopy: a comparative audit of efficacy. Br Med J Clin Res Ed 1994; 1998; 6629: 1095-1096
31. Mansi C, Mela GS, Pasini D, et al. Patterns of dyspepsia in patients with no clinical evidence of organic diseases. Dig Dis Sci 1990; 35: 1452-1458
32. Bytzer P, Hansen JM, Havelund T, et al. Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement. Eur J Gastroenterol Hepatol 1996; 8: 359-363
33. Adang RP, Ambergen AW, Talmon JL, et al. The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: A study on the clinical presentation of 1147 patients. Digestion 1996; 57: 118-134
34. Heading RC, Wager E, Tooley PJ. Reliability of symptom assessment in dyspepsia. Eur J Gastroenterol Hepatol 1997; 9: 779-781
35. Davenport PM, Morgan AG, Darnborough A, de Dombal FT. Can preliminary screening of dyspeptic patients allow more effective use of investigational techniques? Brit Med J Clin Res Ed 1994; 1985; 6463: 217-220
36. Numans ME, Van der Graaf Y, de Wit NJ, et al. How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy. Family Practice 1994; 11: 382-388
37. Muris JW, Starmans R, Pop P. Discriminant value of symptoms in patients with dyspepsia. J Fam Pract 1994; 38: 139-143
38. Dooley CP, Cohen H, Fitzgibbons PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med 1989; 321: 1562-1566
39. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-1501
40. Gasbarrini G, Pretolani S, Bonvicini F, et al. A population based study of Helicobacter pylori infection in a European country: the San Marino study. Relations with gastrointestinal diseases. Gut 1995; 36: 838-844
41. Anonymous. An international association between helicobacter pylori infection and gastric cancer. The Eurogast study group. Lancet 1993; 341: 1359-1362
42. Goodman KJ, Correa P. The transmission of Helicobacter pylori. A critial review of the evidence. Int J Epidemiol 1995; 24: 875-887
43. Kuipers EJ, Pena AS, Van Kamp G, et al. Seroconversion for Helicobacter pylori infection. Lancet 1993; 342: 328-331
44. Megraud F. Epidemiology of Helicobacter pylori infection: where are we in 1995? Eur J Gastroenterol Hepatol 1995; 7: 292-295
45. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-708
46. Peterson WL. Helicobacter pylori and peptic ulcer disease (see comments). (Review) (97 refs). N Engl J Med 1991; 324: 1043-1048
47. Rauws EA. Role of Helicobacter pylori in duodenal ulcer. Drugs 1992; 44: 921-927
48. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-312
49. Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 1994; 150: 177-185
50. Elta GH, Scheiman JM, Barnett JL, et al. Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients. Am J Gastroenterol 1995; 90: 1089-1093
51. Greenberg RE, Bank S. The prevalence of Helicobacter pylori in nonulcer dyspepsia. Importance of stratification according to age. Arch Intern Med 1990; 150: 2053-2055
52. Holtmann G, Goebell H, Holtmann M, Talley NJ. Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 1994; 39: 1090-1098
53. Bouche O. Should Helicobacter pylori be eradicated in a patient with chronic gastritis? (Review) (127 refs) (French). Gastroenterol Clin Biol 1996; 20: S143-S153
54. Armstrong D. Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol Suppl 1996; 215: 38-47
55. McCarthy C, Patchett S, Collins RM, et al. Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci 1995; 40: 114-119
56. Gilvarry J, Buckley MJ, Beattie S, et al. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scan J Gastroenterol 1997; 32: 535-540
57. Sheu BS, Lin CY, Lin XZ, et al. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment. Am J Gastroenterol 1996; 91: 441-447
58. Lazzaroni M, Bargiggia S, Sangaletti O, et al. Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. A clinical endoscopic study. Dig Dis Sci 1996; 41: 1589-1594
59. O'Morain C, Gilvarry J. Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. (Review) (40 rfs). Scand J Gastroenterol Suppl 1993; 196: 30-33
60. Veldhuyzen van Zanten SJ, Malatjalian D. The effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia (NUD): a randomized, double blind, placebo-controlled trial (abstract). Gastroenterology 1995; 108: A250
61. Greenberg PD. Prospective, double-blind treatment of Helicobacter pylori in patients with non-ulcer dyspepsia. (Abstract). Gastroenterology 1996; 110: A123
62. Schubert TT, Schubert AB, Ma CK. Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy. Gastrointest Endosc 1992; 38: 357-360
63. McColl KEL. U.K. MRC trial of H. pylori eradication therapy for non-ulcer dyspepsia. (Abstract). Gastroenterology 1998; 114: A222-A222
64. Koelz HR. Treatment of Helicobacter pylori does not improve symptoms of functional dyspepsia. (Abstract). Gastroenterology 1998; 114: A182-A182
65. Bretagne JF. The course of symptoms after eradication of Helicobacter pylori: a one-year follow-up of a cohort of 258 patients with duodenal ulcer or nonulcer dyspepsia. (Abstract). Gastroenterology 1998; 114: A81-A81
66. Talley NJ. Long-term follow-up of patients with non-ulcer dyspepsia after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial. (Abstract). Gastroenterology 1998; 114: A305-A305
67. Anonymous. Nih consensus conference. Helicobacter pylori in peptic ulcer disease. Nih consensus development panel on Helicobacter pylori in peptic ulcer disease. J Am Med Ass 1994; 272: 65-69
68. Dyspepsia Management Guidelines. Brit Society of Gastroenterology. http://www.bsg.org.uk/clinical/data/dmg.htm: 1996
69. Wilcox CM, Schwartz DA. Endoscopic characterization of idiopathic esophageal ulceration associated with human immunodeficiency virus infection. J Clin Gastroenterol 1993; 16: 251-256
70. Megraud F. Advantages and disadvantages of current diagnostic tests for the detection of Helicobacter pylori. Scand J Gastroenterol Suppl 1996; 215: 57-62
71. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharmacy 1993; 12: 34-48
72. Laine L, Chun D, Stein C, et al. The influence of size or number of biopsies on rapid urease test results: a prospective evaluation. Gastrointest Endosc 1996; 43: 49-53
73. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91: 1138-1144
74. Megraud F. The most important diagnostic modalities for Helicobacter pylori, now and in the future. (Review) (4 refs). Eur J Gastroenterol Hepatol 1997; 1: S13-S15
75. Malfertheiner P, Megraud F, O'Morain C, et al. Current european concepts in the management of Helicobacter pylori infection - the Maastricht consensus report. The European Helicobacter pylori study group. Eur J Gastroenterol Hepatol 1997; 9: 1-2
76. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of the American College of Gastroenterology. J Am Med Ass 1996; 275: 622-629
77. Holtmann G, Layer P, Goebell H. Proton-pump inhibitors or h2-receptor antagonists for Helicobacter pylori eradication - a meta-analysis (letter). Lancet 1996; 347: 763
78. Labenz J, Gyenes E, Ruhl GH, Borsch G. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol 1993; 88: 491-495
79. Fennerty MB, Lieberman D, Magaret N, et al. Effectiveness of H. pylori treatment regimens in clinical practice: a community-based outcomes study. (Abstract). Gastroenterology 1997; 112: A14-A14
80. Lee J, O'Morain C. Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease. Eur J Gastroenterol Hepatol 1997; 9: 527-531
81. Rokkas T, Karameris A, Mavrogeorgis A, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41: 1-4
82. Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scan J Gastroenterol 1993; 28: 939-942
83. Jaspersen D, Koerner T, Schorr W, et al. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995; 41: 5-7
84. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594
85. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade-B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577
86. Sackmann M, Morgner A, Rudolph B, et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. Gastroenterology 1997; 113: 1087-1090
87. Veldhuyzen von ZS, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. CMAJ 1997; 156: 1565-1574
88. Lerang F, Moum B, Ragnhildstveit E, et al. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study. Am J Gastroenterol 1997; 92: 653-658
89. Hopkins RJ, Girardi LS, Turney EA, et al. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-1252
90. Vanderhulst RM, Rauws EJ, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori - A prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-1086
91. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-1447
92. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994; 343: 258-260
93. Goulston KJ, Dent OF, Logan J, et al. Use of H2-receptor antagonists in patients with dyspepsia and heartburn: a cost comparison. Med J Aust 1991; 155: 20-26
94. Goodson JD, Lehmann JW, Richter JM, et al. Is upper gastrointestinal radiography necessary in the initial management of uncomplicated dyspepsia? A randomized controlled trial comparing empiric antacid therapy plus patient reassurance with traditional care. J Gen Intern Med 1989; 4: 367-374
95. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343: 811-816
96. Bloom BS. Cross-national changes in the effects of peptic ulcer disease. Ann Intern Med 1991; 114: 558-562
97. Westbrook JI, Rushworth RL. The epidemiology of peptic ulcer mortality 1953-1989: a birth cohort analysis. Intern J Epidemiol 1993; 22: 1085-1092
98. La Vecchia C, Lucchini F, Negri E, et al. The impact of therapeutic improvements in reducing peptic ulcer mortality in Europe. Intern J Epidemiol 1993; 22: 96-106
99. Msika S, Tazi MA, Benhamiche AM, et al. Population-based study of diagnosis, treatment and prognosis of gastric cancer. Brit J Surg 1997; 84: 1474-1478
100. Kahn K. Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American College of Physicians. Ann Intern med 1985; 102: 266-269
101. American Society for Gastrointestinal Endoscopy. The role of endoscopy in the management of the patient with peptic ulcer disease. Guidelines for clinical application. Gastrointest Endose 1988; 34: 4S-25S
102. Bytzer P. Diagnosing dyspepsia: any controversies left? Gastroenterology 1996; 110: 302-306
103. Tham TC. Application of serological screening for Helicobacter pylori in reducing endoscopy workload. Gastroenterology 1993; 104: A26
104. Lassen AT. H. Pylori "test and treat" or prompt endoscopy for dyspeptic patients in primary care. A randomized controlled trial of two management strategies: one year follow-up. (Abstract). Gastroenterology 1998; 114: A196-A196
105. Jones RH. A Helicobacter test and treat strategy: costs and outcomes in a randomized controlled trial in primary care. (Abstract). Gastroenterology 1998; 114: A20-A20
106. Ofman JJ, Etchason J, Fullerton S, et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia - clinical and economic consequences. Ann Intern Med 1997; 126: 280-291
107. Briggs AH, Sculpher MJ, Logan RP, et al. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. Br Med J 1996; 312: 1321-1325
108. Fullerton F. Empiric antibiotic therapy versus early endoscopy in dyspeptic patients with positive serologic test for Helicobacter pylori: a decision analysis. (Abstract). Gastroenterology 1995; 108: A15
109. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-249
110. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis. Yale Journal of Biology & Medicine 1996; 69: 187-195
111. Eckardt VF, Giessler W, Kanzler G, Bernhard G. Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers and gastric cancer? Cancer 1992; 69: 301-305
112. Farinati F, Cardin F, Di Mario F, et al. Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer: significance of the presence of epithelial dysplasia. J Surg Oncol 1987; 36: 263-267
113. Tragardh B, Haglund U. Endoscopic diagnosis of gastric ulcer. Evaluation of the benefits of endoscopic follow-up observation for malignancy. Acta Chir Scand 1985; 15: 37-41
114. Bytzer P. Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile? Scandinavian Journal of Gastroenterology 1991; 26: 1193-1199
115. Pruitt RE, Truss CD. Endoscopy, gastric ulcer, and gastric cancer. Follow-up endoscopy for all gastric ulcers? Dig Dis Sci 1993; 38: 284-288
116. Hansson LE, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996; 335: 242-249
117. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci 1995; 40: 1345-1350
118. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori (editorial; comment). N Engl J Med 1993; 328: 349-350
119. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796
120. Larkai EN, Smith JL, Lidsky MD, Graham DY. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-1158
121. Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: toward the development of more selective NSAIDs. Drug News and Perspectives (Barcelona) 1994; 7: 501-512
122. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Brit J Rheumatol 1996; 35: 68-77
123. Roth SH, Bennett R, Caldron P, et al. A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol 1994; 21: 1118-1123
124. Porro GB, Montrone F, Petrillo M, et al. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol 1995; 90: 1485-1488
125. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs (see comments). N Engl J Med 1992; 327: 749-754
126. Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991; 100: 653-657
127. Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology 1992; 102: 1899-1905
128. Chan FK, Sung JJ, Chung SC, et al. Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979
129. Lai KC. Eradication of Helicobacter pylori did not accelerate the healing of gastric and duodenal ulcers/erosions in patients on long-term continuous nonsteroidal anti-inflammatory drugs. (Abstract). Gastroenterology 1998; 114: A192
130. Lai KC. Can eradication of Helicobacter Pylori prevent future development of peptic ulcers in patients receiving long-term continuous nonsteroidal anti-inflammatory drugs. (Abstract). Gastroenterology 1998; 114: A192
131. Hawkey CJ, Tullassay Z. Failure of Helicobacter Pylori eradication to influence site-specific relapse in high risk NSAID users: results of a large six month double blind randomized controlled clinical trial. (Abstract). Gastroenterology 1998; 114: A145
132. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury - a meta-analysis of randomized controlled clincal trials. (Abstract). Arch Intern Med 1996; 156: 2321-2332
133. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996; 334: 1435-1439
134. Agrawal NM, Van Kerckhove HE, Erhardt LJ, Geis GS. Misoprostol coadministered with diclofenac for prevention of gstroduodenal ulcers. a one-year study. Dig Dis Sci 1995; 40: 1125-1131
135. Hudson N, Taha AS, Russell RI, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration (see comments). Gastroenterology 1997; 112: 1817-1822
136. Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scan J Gastroenterol 1996; 31: 753-758
137. Yeomans ND, Tulassay Z, Juhasz L, et al. A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. N Engl J Med 1998; 338: 719-726
138. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs. N Engl J Med 1998; 338: 727-734
139. Martin LF. Stress ulcers are common after aortic surgery. Endoscopy evaluation of prophylactic therapy. Am Surg 1994; 60: 169-174
140. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. J Am Med Ass 1996; 275: 308-314
141. Zandstra DF, Stoutenbeek CP. The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis. A prospective cohort study (see comments). Intens Care Med 1994; 20: 335-340
142. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330: 377-381
143. Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci 1997; 42: 1255-1259
144. Schepp W, Schusdziarra V, Classen M. (Stress ulcer prophylaxis 1995. Balancing between gastrointestinal bleeding and nosocomial pneumonia.) Dtsch Med Wochenstr 1995; 120: 573-579
145. Marrone GC, Silen W. Pathogenesis, diagnosis and traetment of acute gastric mucosal lesions. Clin Gastroenterol 1984; 13: 635-650
146. De Bosset V, Gonvers JJ, Froehlich F, et al. Appropriateness of gastroscopy: Bleeding and dysphagia. Endoscopy 1999; 31: 615-622
147. Hudson N. Excess long-term mortality in patients with ulcer complications. Lancet 1997; 349: 968-969
148. Svanes C, Lie RT, Lie SA, et al. Survival after peptic ulcer perforation: a time trend analysis. J Clin Epidemiol 1996; 49: 1363-1371
149. Svanes C, Salvesen H, Stangeland L, et al. Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics. Gut 1993; 3: 1666-1671
150. International Agency for Research on Cancer. Atlas of cancer mortality in the European Economic Community. In: Smans M, Muir CS, Boyle P (eds). Lyon, France: IARC, 1992
151. International Agency for Research on Cancer. Atlas of cancer mortality in Central Europe. In: Zatonski W, Smans M, Tyczynski J, et al. (eds). Lyon, France: IARC, 1996
152. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333: 32-41
153. Gasbarrini G, Genta RM, Anti M, et al. Update on Helicobacter pylori research. Malignancies. Eur J Gastroenterol Hepatol 1997; 9: 621-623
154. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Brit Med J 1991; 302: 1302-1305
155. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131
156. Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132-1136
157. Blaser MJ, Chyou PH, Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res 1995; 55: 562-565
158. Matley PJ, Dent DM, Madden MV, et al. Gastric carcinoma in young adults. Ann Surg 1988; 208: 593-596
159. Moreno-Otero R, Rodriguez S, Carbo J, et al. Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma. J Surg Oncol 1987; 36: 130-133
160. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists. Lancet 1997; 349: 1725-1729
161. Farinati F, Rugge M, Di Mario F, et al. Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients, a prospective study. i. g. g. e. d.-interdisciplinary group on gastric epithelial dysplasia. Endoscopy 1993; 25: 261-264
162. Hallissey MT, Allum WH, Jewkes AJ, et al. Early detection of gastric cancer. Brit Med J 1990; 301: 513-515
163. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary Pharmacology & Therapeutics 1994; 8: 35-43
164. Iwao T, Toyonaga A, Ikegami M, et al. McCormack's endoscopic signs for diagnosing portal hypertension: comparison with gastroesophageal varices. Gastrointest Endosc 1994; 40: 470-473
165. Ziegler K, Sanft C, Zimmer T, et al. Comparison of computed tomography, endosonography, and intraoperative assessment in tn staging of gastric carcinoma. Gut 1993; 34: 604-610
166. Dittler HJ, Siewert JR. Role of endoscopic ultrasonography in gastric carcinoma. Endoscopy 1993; 25: 162-166
167. Grimm H, Binmoeller KF, Hamper K, et al. Endosonography for preoperative locoregional staging of esophageal and gastric cancer. Endoscopy 1993; 25: 224-230